DoW Peer Reviewed Medical, Clinical Trial Award

Funding Opportunity Number: HT942526PRMRPCTA

About the Opportunity

The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have significant impact on the treatment and management of a disease or condition addressed in one of the congressionally directed FY26 PRMRP topic areas and FY26 PRMRP strategic goals.

Distinctive Features

• Must support a clinical trial.
• Supports two application categories: Clinical Trial Only or Clinical Trial with Planning Phase.
• The Clinical Trial with Planning Phase option supports final regulatory and planning activities necessary before initiating the clinical trial. The planning phase cannot be used to finalize the intervention or support animal studies.
• Applications with existing regulatory approvals (submitting under Clinical Trial Only) may be prioritized over those requesting the Planning Phase.
• Animal studies are not supported; all preclinical empirical laboratory work must be completed prior to the award start date.
• Supports three funding levels, each offered with or without a Planning Phase:
  • Funding Level 1: Phase 0 or phase 1 clinical trials, or non-phased trials with fewer than 100 participants.
  • Funding Level 2: Phase 2 clinical trials, or non-phased trials with fewer than 300 participants.
  • Funding Level 3: Phase 3 clinical trials, or non-phased trials with more than 300 participants.

Funding Details

• Approximately $94.5M expected to fund roughly 9 awards.
• Cost caps per award:
  • $800,000 for the planning phase of a Clinical Trial with Planning Phase.
  • $6M for Funding Level 1.
  • $10M for Funding Level 2.
  • $20M for Funding Level 3.
• Maximum period of performance:
  • 4 years for the clinical trial.
  • 12 months for the planning phase.
• Awards will be funded with FY26 funds, expiring September 30, 2032, and made no later than September 30, 2027.

Eligibility

Unrestricted (open to any type of entity), subject to additional clarifications in the full announcement.